Survival and reproductive outcome of childbearing age ovarian cancer patients taking fertility-sparing surgery
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20223476Keywords:
Ovarian cancer, Fertility-sparing surgery, Hysterectomy, OophorectomyAbstract
Background: Surgical management of ovarian cancer includes total hysterectomy and bilateral salpingo-oophorectomy which results in the loss of fertility. Fertility-sparing surgery in the reproductive aged women with early-stage ovarian cancer with favourable histology has been proposed by American College of Obstetrics and Gynecology and European Society for Medical Oncology. We sought to access the survival and fertility outcome of Korean women in their reproductive age who undertook fertility-sparing surgery.
Methods: Based on the Korean National Insurance Claims Data and the National Health Information Database, 328 women with newly developed ovarian cancer in 2010 were followed up for the survival and pregnancy outcome until 2020. Patients who were diagnosed with cancer or underwent hysterectomy before 2010 were excluded. The control group consisted of 552 women matched by age, economic status and place of living.
Results: Out of 120, 10 deaths occurred in the fertility-sparing surgery group showing a survival rate of 91.7%. Women undertaking fertility-sparing surgery had a lower chance of delivering a new-born compared to the control group (OR 0.46; 95% CI 0.26-0.81). Diagnosis of infertility, ectopic pregnancy, and abortion appeared higher in the fertility-sparing surgery group, but it did not reach a statistical significance.
Conclusions: The pregnancy rate of the ovarian cancer patients with fertility-sparing surgery was lower than that of women without ovarian cancer. Undergoing fertility-sparing surgery per se should not deter women of trying to get pregnant as the pregnancy outcome indicators do not show statistically significant differences compared to the control group.
References
Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES, et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017. Cancer Res Treat. 2020;52(2):335-50.
Rodriguez M, Nguyen HN, Averette HE, Steren AJ, Penalver MA, Harrison T, et al. National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age. Cancer. 1994;73(4):1245-50.
Duska LR, Chang YC, Flynn CE, Chen AH, Goodman A, Fuller AF, et al. Epithelial ovarian carcinoma in the reproductive age group. Cancer. 1999;85(12):2623-9.
National Cancer Institute. Cancer Stat Facts: Ovarian cancer, 2021. Available at: https://seer. Cancer.gov/staff acts/html/ovary.html. Accessed on 12 December 2022.
Schlaerth AC, Chi DS, Poynor EA, Barakat RR, Brown CL. Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19(7):1199-204.
Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2020;87(1):1-7.
Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol. 2007;25(20):2873-83.
Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009;115(18):4118-26.
Satoh T, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol. 2010;28(10):1727-32.
Gershenson DM. Treatment of ovarian cancer in young women. Clin Obstet Gynecol. 2012;55(1):65-74.
Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol. 2008;110(3):345-53.
Morice P, Wicart-Poque F, Rey A, El-Hassan J, Pautier P, Lhommé C, et al. Results of conservative treatment in epithelial ovarian carcinoma. Cancer. 2001;92(9):2412-8.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol. 2007;110(1):201-14.
Aebi S, Castiglione M, ESMO Guidelines Working Group. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(2):14-6.
Gershenson DM. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol. 1988;6(2):270-5.
Kanazawa K, Suzuki T, Sakumoto K. Treatment of malignant ovarian germ cell tumors with preservation of fertility: reproductive performance after persistent remission. Am J Clin Oncol. 2000;23(3):244-8.
Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol. 2011;61:212-36.
Gershenson DM, Hartmann LC, Young RH. Ovarian sex cord-stromal tumors. In: Barakat RR, Markman M, Randall ME, eds. Principles and Practice of Gynecologic Oncology. Philadelphia: Lippincott Williams and Wilkins; 2009: 855-873.
Gershenson DM. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr. 2005;(34):43-7.
Fleming GF, Ronnett BM, Seidman J. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, eds. Principles and Practice of Gynecologic Oncology. Philadelphia: Lippincott Williams and Wilkins; 2009: 763-835.
